Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfasalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.57 |
| ▸ | SLC7A11 | Q9UPY5 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfasalazine SCHEMBL29861725 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL18256143 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL31174674 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL5664970 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL10289061 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL4515 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL4514 | 1.00 | SLC7A11 (1.00) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL20994010 | 0.99 | SLC7A11 (0.98) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL21055748 | 0.99 | SLC7A11 (0.98) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 | |
| Sulfasalazine SCHEMBL5930194 | 0.99 | SLC7A11 (0.98) | SLC7A11ALDH1A1CYP2C9MEN1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005079419-A2 | METHODS OF TREATING IMMUNOPATHOLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-01 | — | — | WO | claimed |
| CN-118271323-A | WRN inhibitors | 苏州浦合医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271322-A | WRN helicase inhibitors | 苏州浦合医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271307-A | PRMT5-MTA inhibitors | 苏州浦合医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | KAHRS, Bjoern Colin (CH) | 2023-06-22 | — | — | US | disclosed |
| WO-2021053343-A1 | Methods for predicting patient response to DMARDs | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2021-03-25 | — | — | WO | disclosed |
| US-20200392084-A1 | SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME | ABU IZZA KHAWLA (US) | 2020-12-17 | — | — | US | disclosed |
| CN-111971272-A | Sulfasalazine salt compositions and methods of use thereof | 库布拉·阿布-伊扎 | 2020-11-20 | — | — | CN | disclosed |
| EP-3694837-A1 | SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME | Abu-Izza, Khawla (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-2582683-A1 | TREATMENT OF GOUT AND HYPERURICEMIA | Ardea Biosciences, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130059868-A1 | TREATMENT OF GOUT | Ardea Biociences, Inc. (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2560642-A2 | TREATMENT OF GOUT | Ardea Biosciences, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2437596-A1 | SKIN TREATMENT COMPOSITIONS | Ex-Tek, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2410998-A2 | DRUG DEPOTS FOR TREATMENT OF PAIN AND INFLAMMATION IN SINUS AND NASAL CAVITIES OR CARDIAC TISSUE | Medtronic, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011159732-A1 | TREATMENT OF GOUT AND HYPERURICEMIA | ARDEA BIOSCIENCES,INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011126852-A2 | TREATMENT OF GOUT | ARDEA BIOSCIENCES, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110250206-A1 | MARKERS FOR DETERMINATION OF PATIENT RESPONSIVENESS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2011-10-13 | — | — | US | disclosed |
| WO-2010141711-A1 | SKIN TREATMENT COMPOSITIONS | EX-TEK, LLC (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010111178-A2 | DRUG DEPOTS FOR TREATMENT OF PAIN AND INFLAMMATION IN SINUS AND NASAL CAVITIES OR CARDIAC TISSUE | MEDTRONIC, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392084-A1 | SULFASALAZINE SALT COMPOSITIONS AND METHODS OF USING THE SAME | STS, SCLY, SCN5A | PTGS1 1042/4885PTGS2 895/4885SLC7A11 31/4885 |
| US-20130059868-A1 | TREATMENT OF GOUT | SLC10A1, UGP2, URB2 | PTGS1 1330/4885PTGS2 1783/4885SLC7A11 1237/4885 |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | PTGS1 119/4885PTGS2 134/4885SLC7A11 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.